TCM
NBIX icon

Traub Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Traub Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12
Closed -$1.51K – 385
2025
Q2 		$1.51K Buy
+12
New +$1.38K ﹤0.01% 495

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Traub Capital Management's NBIX Position: Q3 2025 in Review

Traub Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 12 shares — an estimated $1.51K sold.

Traub Capital Management first reported a position in NBIX in Q2 2025 and held it in 1 quarter. The position peaked at $1.51K in Q2 2025. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Traub Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Traub Capital Management sold 12 Neurocrine Biosciences shares in Q3 2025, an estimated $1.51K.
  • Traub Capital Management first reported a position in Neurocrine Biosciences in Q2 2025 and held it in 1 quarter.
  • Traub Capital Management's Neurocrine Biosciences position peaked at $1.51K in Q2 2025.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Traub Capital Management's 13F filing for Q3 2025, filed 30 Oct 2025.